Having trouble accessing articles? Reset your cache.

Amphinex: Additional Phase I/II data

Data from the fourth dose group of an open-label, dose-escalation, U.K. Phase I/II trial showed that 2 of

Read the full 184 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE